Skip to main content

Table 4 Grade 3 and 4 hematologic adverse events

From: Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

Neutropenia, G-CSF support 5 (17.9 %), 11 (39.3 %)
Anemia 7 (25.0 %)
Thrombocytopenia 7 (25.0 %)
  1. Data are expressed as the number (percentage of total group)